Pfizer: Carcinoma, Non-Small-Cell Lung trials

The registry lists 158 Carcinoma, Non-Small-Cell Lung studies with Pfizer as lead sponsor. 15 are open to participants now and 72 have results posted.

Phase 1 69Phase 2 58Phase 3 18Phase 4 4No phase 22(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.RecruitingNCT07903415Phase 1
• A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight LossNot yet recruitingNCT07663630Phase 1
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCRecruitingNCT07489066Phase 2
• Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersRecruitingNCT07227298Phase 1/2
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT07222566Phase 3
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)RecruitingNCT07144280Phase 3
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1
• This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.RecruitingNCT06758401Phase 3
• Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextRecruitingNCT06487078Not applicable
• A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsRecruitingNCT06131840Phase 1
• Post Marketing Surveillance(PMS) Study of Lorviqua in KoreaRecruitingNCT05599412
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
• Study of PF-07248144 in Advanced or Metastatic Solid TumorsRecruitingNCT04606446Phase 2
• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsRecruitingNCT04557449Phase 2
• A Study of Sigvotatug Vedotin in Advanced Solid TumorsRecruitingNCT04389632Phase 1
• A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be ControlledCompletedNCT06282991Results posted
• A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.CompletedNCT05834348Results posted
• Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15CompletedNCT05546476Phase 2Results posted
• Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedNCT05061537Phase 1Results posted
• A Study of SEA-CD40 Given With Other Drugs in CancersCompletedNCT04993677Phase 2Results posted
• Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese PatientsCompletedNCT04979988Results posted
• Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and AnorexiaCompletedNCT04803305Phase 1Results posted
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedNCT04585815Phase 1/2Results posted
• Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive, not recruitingNCT04579380Phase 2Results posted
• A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain InvolvementTerminatedNCT04543188Phase 1Results posted
• Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in IndiaCompletedNCT04541706Phase 4Results posted
• Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsCompletedNCT04511533Phase 4Results posted
• Treatment Resistance Following Anti-cancer TherapiesTerminatedNCT04436120Not applicableResults posted
• Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment PatternsCompletedNCT04351334Results posted
• Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.CompletedNCT04299048Phase 1Results posted
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesCompletedNCT04181788Phase 1/2Results posted
• Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)CompletedNCT04155541Results posted
• A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsTerminatedNCT04032704Phase 2Results posted
• An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung CancerCompletedNCT03915951Phase 2Results posted
• A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in ChinaCompletedNCT03909971Phase 2Results posted
• Descriptive Observational Study ALK-2016-CPHGCompletedNCT03718117Results posted
• Vaccine-Based Immunotherapy Regimen For NSCLC and TNBCTerminatedNCT03674827Phase 1Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsTerminatedNCT03330405Phase 1/2Results posted
• Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced MalignanciesTerminatedNCT03317496Phase 1/2Results posted
• Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCActive, not recruitingNCT03052608Phase 3Results posted
• Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)CompletedNCT02679170Results posted
• PF-06671008 Dose Escalation Study in Advanced Solid TumorsTerminatedNCT02659631Phase 1Results posted
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedNCT02554812Phase 1/2Results posted
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLCCompletedNCT02364999Phase 3Results posted
• Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)TerminatedNCT02349633Phase 1/2Results posted
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
• Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North AfricaCompletedNCT02304406Results posted
• A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsCompletedNCT02222922Phase 1Results posted
• A Study Of PF-06664178 In Patients With Advanced Solid TumorsTerminatedNCT02122146Phase 1Results posted
• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular AlterationsCompletedNCT01970865Phase 1/2Results posted
• Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCCompletedNCT01945021Phase 2Results posted
• A Study Of PF-06263507 In Patients With Advanced Solid TumorsTerminatedNCT01891669Phase 1Results posted
• MEK162 for Patients With RAS/RAF/MEK Activated TumorsCompletedNCT01885195Phase 2Results posted
• A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01858389Phase 2Results posted
• ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.CompletedNCT01774721Phase 3Results posted
• A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsCompletedNCT01639001Phase 3Results posted
• Safety And Efficacy Of Crizotinib (Regulatory Post Marketing Commitment Plan)CompletedNCT01597258Results posted
• Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PROCompletedNCT01465802Phase 2Results posted
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedNCT01360554Phase 3Results posted
• A Study Of PF-05082566 As A Single Agent And In Combination With RituximabCompletedNCT01307267Phase 1Results posted
• A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung CancerCompletedNCT01121575Phase 1Results posted
• Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung CancerCompletedNCT00965731Phase 1Results posted
• An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneCompletedNCT00932893Phase 3Results posted
• An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneCompletedNCT00932451Phase 2Results posted
• A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenCompletedNCT00769067Phase 2Results posted
• Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung CancerCompletedNCT00768755Phase 1/2Results posted
• Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung CancerCompletedNCT00735904Phase 2Results posted
• Trial Of CP-751, 871 And Erlotinib In Refractory Lung CancerTerminatedNCT00673049Phase 3Results posted
• Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung CancerCompletedNCT00603538Phase 1Results posted
• A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.CompletedNCT00600821Phase 2Results posted
• Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma HistologyTerminatedNCT00596830Phase 3Results posted
• Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00560573Phase 1Results posted
• Trial Of PF-00299804 In Patients With Advanced Refractory Lung CancerCompletedNCT00553254Phase 2Results posted
• PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And ErlotinibCompletedNCT00548093Phase 2Results posted
• A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib AloneCompletedNCT00457392Phase 3Results posted
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
• Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain MetastasesCompletedNCT00372775Phase 2Results posted
• A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib AloneCompletedNCT00265317Phase 2Results posted
• Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung CancerCompletedNCT00147537Phase 1/2Results posted
• A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung CancerCompletedNCT00113516Phase 2Results posted
• Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT00094094Phase 2Results posted
• A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First TreatmentActive, not recruitingNCT07567352
• A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCCompletedNCT07556549
• A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesTerminatedNCT06974734Phase 1
• A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedNCT06870487Phase 1
• A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.TerminatedNCT06704724Phase 1
• A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.CompletedNCT06678555
• A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedNCT06580938Phase 1
• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study of SGN-MesoC2 in Advanced Solid TumorsTerminatedNCT06466187Phase 1
• A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationTerminatedNCT06448364Phase 1
• A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Active, not recruitingNCT06447662Phase 1
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1